CN118946564A - 高纯度化合物的制造方法及纯化方法 - Google Patents

高纯度化合物的制造方法及纯化方法 Download PDF

Info

Publication number
CN118946564A
CN118946564A CN202380031604.XA CN202380031604A CN118946564A CN 118946564 A CN118946564 A CN 118946564A CN 202380031604 A CN202380031604 A CN 202380031604A CN 118946564 A CN118946564 A CN 118946564A
Authority
CN
China
Prior art keywords
pyrido
dihydro
benzodiazepine
salt
diethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380031604.XA
Other languages
English (en)
Chinese (zh)
Inventor
大野敦嗣
本田崇宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of CN118946564A publication Critical patent/CN118946564A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202380031604.XA 2022-03-30 2023-03-29 高纯度化合物的制造方法及纯化方法 Pending CN118946564A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022-056754 2022-03-30
JP2022056754 2022-03-30
PCT/JP2023/012761 WO2023190663A1 (ja) 2022-03-30 2023-03-29 高純度化合物の製造方法および精製方法

Publications (1)

Publication Number Publication Date
CN118946564A true CN118946564A (zh) 2024-11-12

Family

ID=88202044

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380031604.XA Pending CN118946564A (zh) 2022-03-30 2023-03-29 高纯度化合物的制造方法及纯化方法

Country Status (7)

Country Link
US (1) US20250214992A1 (https=)
EP (1) EP4506347A4 (https=)
JP (1) JPWO2023190663A1 (https=)
KR (1) KR20240168375A (https=)
CN (1) CN118946564A (https=)
TW (1) TW202402753A (https=)
WO (1) WO2023190663A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3409237A1 (de) 1984-03-14 1985-09-19 Dr. Karl Thomae Gmbh, 7950 Biberach Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3626095A1 (de) * 1986-07-31 1988-02-11 Thomae Gmbh Dr K Neue substituierte pyrido(2,3-b)(1,4)benzodiazepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5716952A (en) 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
JPH09318772A (ja) 1996-05-28 1997-12-12 Rhythm Watch Co Ltd 装飾装置
JP2017535545A (ja) * 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物
CN114302726A (zh) 2020-08-04 2022-04-08 参天制药株式会社 用于治疗近视、预防近视及/或抑制近视发展的药剂
JP7253813B2 (ja) 2020-08-07 2023-04-07 株式会社ユニバーサルエンターテインメント 遊技機
WO2022080397A1 (ja) * 2020-10-14 2022-04-21 参天製薬株式会社 安定な医薬組成物
EP4501329A4 (en) * 2022-03-30 2026-03-25 Santen Pharmaceutical Co Ltd METHOD FOR STERILIZING AND PACKAGING A PHARMACEUTICAL PREPARATION

Also Published As

Publication number Publication date
EP4506347A4 (en) 2026-03-25
WO2023190663A1 (ja) 2023-10-05
US20250214992A1 (en) 2025-07-03
KR20240168375A (ko) 2024-11-29
TW202402753A (zh) 2024-01-16
JPWO2023190663A1 (https=) 2023-10-05
EP4506347A1 (en) 2025-02-12

Similar Documents

Publication Publication Date Title
US20080085903A1 (en) Novel crystalline forms of aripiprazole
JP6916207B2 (ja) インダゾールの合成
EP4434582A2 (en) Crystal of pyrrolidine compound
EP3022209B1 (en) Dolutegravir potassium salt
JPWO2005075474A1 (ja) コハク酸ソリフェナシン含有組成物
US8664243B2 (en) Sulfonamide compound and crystal thereof
EP3360858B1 (en) Process for producing an aminopyrrolidine derivative
HUE025930T2 (en) Process for the preparation of argatroban monohydrate
WO2021233783A1 (de) Verfahren zur herstellung von butyl-(5s)-5-({2-[4-(butoxycarbonyl)phenyl]ethyl}[2-(2-{[3-chlor-4'-(trifluormethyl)[biphenyl]-4-yl]methoxy}phenyl)ethyl]amino)-5,6,7,8-tetrahydrochinolin-2-carboxylat
EP3271337B1 (de) Verfahren zur herstellung von (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluormethyl)phenyl]-1,2,3,4-tetrahydro pyrimidin-5-carbonitril
CN118946564A (zh) 高纯度化合物的制造方法及纯化方法
CA2608078A1 (en) Crystal of aminopyrrolidine derivative and prodcution method thereof
JP5065020B2 (ja) レボフロキサシンまたはその水和物の製造方法
EP3202772B1 (en) Crystal of a complex of l-proline/sodium-glucose cotransporter 2 inhibitor
EP1626051B1 (en) Crystals of quinolinecarboxylic acid derivative solvate
JP2012020970A (ja) ｛２−アミノ−１，４−ジヒドロ−６−メチル−４−（３−ニトロフェニル）−３，５−ピリジンジカルボン酸３−（１−ジフェニルメチルアゼチジン−３−イル）エステル５−イソプロピルエステル｝の製造方法
EP3397618B1 (en) Process for making crystalline form a of gefitinib
CN112876530A (zh) 一种地屈孕酮中间体的晶型及其制备方法
DE60303603T2 (de) Benzolsulfonatsalz eines morpholinharnstoff-derivats zur verwendung als ccr-3 antagonist bei der behandlung von entzündlichen erkrankungen
WO2020016827A1 (en) Purified crystalline detomidine hydrochloride monohydrate, anhydrate and free base with low amounts of iso-detomidine and other impurities by recrystallisation in water
US20070265335A1 (en) Polymorphs of 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsufonyl)amino]-n-methyl-1-benzofuran-3-carboxamide and methods of making the same
KR101386530B1 (ko) 순도 및 수율이 향상된3-아미노-9,13ｂ디하이드로-1Ｈ-디벤즈-[ｃ,ｆ]이미다조[1,5-ａ]-아제핀 염산염의 제조방법
TW201815779A (zh) （ｒ）－５－（３，４－二氟苯基）－５－〔（３－甲基－２－氧代吡啶－１（２ｈ）－基）甲基〕咪唑啶－２，４－二酮之製造方法及用於該製造之中間體
EP4725951A1 (en) Crystal form of steroid compound and use thereof
EP2154137A1 (en) Crystalline form of moxifloxacin base

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination